Barclays PLC Buys 46,880 Shares of Certara, Inc. (NASDAQ:CERT)

Barclays PLC lifted its stake in shares of Certara, Inc. (NASDAQ:CERT) by 198.3% during the third quarter, HoldingsChannel reports. The firm owned 70,525 shares of the company’s stock after acquiring an additional 46,880 shares during the quarter. Barclays PLC’s holdings in Certara were worth $825,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. The Manufacturers Life Insurance Company increased its holdings in shares of Certara by 4.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company’s stock worth $317,000 after acquiring an additional 975 shares during the last quarter. Nicolet Advisory Services LLC increased its holdings in shares of Certara by 6.6% during the 3rd quarter. Nicolet Advisory Services LLC now owns 24,831 shares of the company’s stock worth $273,000 after acquiring an additional 1,531 shares during the last quarter. KBC Group NV increased its holdings in shares of Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after acquiring an additional 1,584 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Certara by 112.3% during the 3rd quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock worth $46,000 after acquiring an additional 2,076 shares during the last quarter. Finally, Everence Capital Management Inc. increased its holdings in shares of Certara by 21.0% during the 3rd quarter. Everence Capital Management Inc. now owns 14,910 shares of the company’s stock worth $175,000 after acquiring an additional 2,590 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Barclays decreased their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Friday, September 27th. Finally, Robert W. Baird decreased their target price on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $15.92.

Certara Stock Performance

Shares of NASDAQ CERT opened at $11.96 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The stock’s fifty day moving average price is $10.86 and its two-hundred day moving average price is $11.95. Certara, Inc. has a one year low of $9.41 and a one year high of $19.87. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of -59.80, a P/E/G ratio of 5.86 and a beta of 1.52.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. During the same period in the prior year, the firm posted $0.06 EPS. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. On average, equities analysts forecast that Certara, Inc. will post 0.28 EPS for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.